Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.079 AUD | -1.25% | -1.25% | -45.52% |
Apr. 30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
Apr. 30 | Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-44.83% | 108M | C | ||
+7.93% | 219B | B | ||
+7.53% | 183B | B- | ||
+15.20% | 136B | B- | ||
+27.02% | 107B | A- | ||
-1.14% | 63.07B | A- | ||
+7.23% | 52.55B | B+ | ||
+12.58% | 51.28B | B+ | ||
+1.61% | 41.21B | A | ||
+5.32% | 36.43B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IPD Stock
- Ratings ImpediMed Limited